Hepatitis Therapeutics Market Report

Hepatitis Therapeutics Market Analysis By Disease Type (A, B, C) By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2014 - 2025

Published: April 2017  |  80 Pages  |  Format: PDF  |  Report ID: GVR-1-68038-449-9

Industry Insights

The global hepatitis therapeutics market size was valued at USD 19.56 billion in 2016, and is expected to witness significant growth over the forecast period. The key drivers include the growing prevalence of viral hepatitis, growing number of autoimmune diseases, rise in geriatric population, and rise in healthcare expenditures across the globe.

Hepatitis is the inflammation of liver tissue caused due to viral infection, excessive alcohol consumption, autoimmune diseases, toxins, medication errors, and nonalcoholic steatohepatitis. According to the WHO, globally around 400 million people are infected with at least one form of hepatitis and every year nearly 1.4 people die due to the condition. This is generally classified into two types based on the duration for which the patient suffers. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis.

U.S. hepatitis therapeutics market by disease type, 2014 - 2025 (USD Million)

U.S. hepatitis therapeutics market

The hepatitis therapeutics market by disease type is categorized as A, B, C, and others. The others segment includes the estimates for the D and E, which occur relatively rarely compared to the other three conditions. Hepatitis A is a viral disease transmitted through ingestion of contaminated water, food, or through direct contact with an infected person. As per the WHO, nearly 90% of the children in developing countries with poor hygiene & sanitary conditions have been infected with A type before reaching the 10 years of age.

Due to high prices quoted by the drug manufacturers, access to treatments has been limited to people who have a high-income level. The introduction of generic versions of hepatitis C drugs has changed the market dynamics across the globe. With more number of people being able to afford the generic versions, the usage rates of its drugs are expected to grow rapidly over the next few years.

Disease Type Insights

Type B is a viral infection, which attacks the liver and can lead to acute & chronic liver disease. As per the WHO, an estimated 240 million people have chronic hepatitis B and more than 686,000 people die every year due to complications arising from it. The virus can be transmitted through blood and other body fluids of an infected person.

The Hepatitis D Virus (HDV) is a Ribonucleic Acid (RNA) virus and needs the help of type B Virus (HBV) to replicate & proliferate in the body. Across the globe, around 15 million people are co-infected with HDV & HBV and presently no effective medication is available for hepatitis D. Therefore, immunization against B is strongly recommended to prevent both type B and D.

Hepatitis C leads to the most serious complications compared to A and B. As per the WHO estimates, nearly 130 to 150 million are impacted by C infection globally. Moreover, a significant number of hepatitis C patients develop liver cancer or liver cirrhosis and nearly 700,000 people die of the C infection & associated conditions.

The introduction of technologically advanced therapeutic products for the treatment of hepatitis has been a major driver for growth. Earlier C was not curable, but with the introduction of products such as Sovaldi and Harvoni, the treatment rate has significantly increased over the past few years. In 2015, these products reportedly had over USD 19 billion sales and the demand for these drugs is expected to remain strong over the next few years.

Regional Insights

The hepatitis therapeutics market is mainly dominated by North America followed by Europe and Asia Pacific. In 2016, the North America market accounted for 42.9% of revenue mainly due to the high demand in the U.S. and the relatively higher prices in the region. The presence of well-developed healthcare infrastructure, reimbursement, and access to most innovative medicines is a crucial factor contributing to the high share.

Global hepatitis therapeutics market by region, 2016 (%)

Global hepatitis therapeutics market

The Asia Pacific market is expected to witness the fastest growth rate of 5.8% over the forecast period. The presence of high disease burden, growing access to medicines, improvement in healthcare & sanitation and rising awareness about the hepatitis vaccination are expected to positively reinforce the growth prospects in the region. For instance, countries such as India, China, Indonesia, and other South Asian economies are constantly increasing their healthcare expenditure and reimbursement coverage to help more people avail quality healthcare services.

The other major factor driving the market include the growing demand for generic products. Gilead has licensed 7 Indian manufacturers to supply some of the hepatitis drugs to different parts of the world. The countries covered as a part of this deal include more than 50% of the type C infected population.

Latin America and Middle East & Africa are also anticipated to witness strong growth due to the high prevalence rates and rise in the import of generic medicines to treat different conditions. As the patient population in the U.S. and other developed regions is declining due to the positive results of using hepatitis C drugs, different manufacturers are expanding their businesses in these regions to cater to the high unmet needs of the region.

Competitive Insights

The global hepatitis therapeutics market is highly competitive and is dominated by players such as Gilead; Merck & Co., Inc.; Johnson & Johnson; Bristol-Myers Squibb Company; and AbbVie Inc. There are several generic manufacturers who are expanding their operations to cater to the high unmet needs of patients in Asia, Middle East, and Latin America.

The growing healthcare costs coupled with the decline in R&D and Medicare budgets are some of the key factors affecting the profitability of market players. The growing awareness about various generic versions available is expected to increase the treatment rate and improve the overall healthcare outcomes.

Another key factor affecting the market growth is the adoption of different pricing models by manufacturers in various parts of the world. In the U.S., the prices are market driven, whereas in countries such as UK and Germany, the government agencies negotiate the prices to maintain affordability and ensure equilibrium between demand and supply. In some other countries, the governments also regulate the prices using price caps, tenders, and other incentives.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2017 - 2025

Market representation                                                 

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Central & South America, Middle East & Africa

Country scope

U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa

Report coverage             

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments covered in the report

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global hepatitis therapeutics market on the basis of disease type and region:

  • Disease Type Outlook (Revenue, USD Million, 2014 - 2025)

    • A

    • B

    • C

    • Others

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Choose License Type

Please choose a licese type to make a report purchase

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified